Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,983 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Bellone S, Jeong K, Halle MK, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich TMP, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Quick CM, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov LB, Siegel ER, Choi J, Schlessinger J, Santin AD. Bellone S, et al. Among authors: scambia g. Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2321898121. doi: 10.1073/pnas.2321898121. Epub 2024 Apr 16. Proc Natl Acad Sci U S A. 2024. PMID: 38625939
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Filetti M, Lombardi P, Falcone R, Giusti R, Giannarelli D, Carcagnì A, Altamura V, Scambia G, Daniele G. Filetti M, et al. Among authors: scambia g. Explor Target Antitumor Ther. 2023;4(6):1136-1144. doi: 10.37349/etat.2023.00187. Epub 2023 Dec 1. Explor Target Antitumor Ther. 2023. PMID: 38213541 Free PMC article.
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. du Bois A, et al. Among authors: scambia g. Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16. Lancet Oncol. 2016. PMID: 26590673 Free article. Clinical Trial.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regináčová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaříková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I. Makker V, et al. Among authors: scambia g. Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234-8. doi: 10.1016/j.ygyno.2024.05.016. Online ahead of print. Gynecol Oncol. 2024. PMID: 38834399
Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result in BRCA1 Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay.
Concolino P, De Paolis E, Rinelli M, Maneri G, Brisighelli F, Trozzi R, Duranti S, Giacò L, Piane M, Preziosi A, Panfili A, Scambia G, Nero C, De Bonis M, Minucci A. Concolino P, et al. Among authors: scambia g. Ann Lab Med. 2024 May 31. doi: 10.3343/alm.2024.0051. Online ahead of print. Ann Lab Med. 2024. PMID: 38826062 Free article. No abstract available.
How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer.
Dinoi G, Garzon S, Weaver A, McGree M, Glaser G, Langstraat C, Kumar A, Weroha J, Garda AE, Shahi M, Palmieri E, Scambia G, Fanfani F, Mariani A. Dinoi G, et al. Among authors: scambia g. Int J Gynecol Cancer. 2024 May 30:ijgc-2023-005217. doi: 10.1136/ijgc-2023-005217. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38821549
Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.
Arcieri M, Vizzielli G, Occhiali T, Giorgiutti C, Tius V, Pregnolato S, Mariuzzi L, Orsaria M, Tulisso A, Damante G, D'Elia AV, Cucinella G, Chiantera V, Fanfani F, Ercoli A, Driul L, Scambia G, Restaino S. Arcieri M, et al. Among authors: scambia g. Eur J Surg Oncol. 2024 May 23;50(7):108436. doi: 10.1016/j.ejso.2024.108436. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 38820923 Free article.
Author's reply to correspondence on "Expanding the Use of HIPEC in Ovarian Cancer at Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis and Perioperative and Oncologic Outcomes" by Mukurdipi Ray et al.
Ghirardi V, Trozzi R, Scambia G, Fagotti A. Ghirardi V, et al. Among authors: scambia g. Ann Surg Oncol. 2024 May 30. doi: 10.1245/s10434-024-15503-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38814550 No abstract available.
1,983 results